Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL27522954 | 0.89 | SSTR4 (0.44) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL27254652 | 0.89 | ACACB (0.54) | SSTR4HDAC1MAPTACACBCYP2C19 | |
| SCHEMBL1900108 | 0.85 | GAA (0.57) | MAPTACACBGAATSHR | |
| SCHEMBL935057 | 0.84 | SSTR4 (0.53) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL8384935 | 0.84 | SSTR4 (0.53) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| Hydrochloric Acid SCHEMBL4323383 | 0.83 | SSTR4 (0.51) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL27279094 | 0.83 | SSTR4 (0.51) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5988810 | 0.82 | SRD5A2 (0.53) | MAPTKMT2AACACBGAATSHR | |
| SCHEMBL24834141 | 0.81 | SSTR4 (0.50) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5315405 | 0.81 | SSTR4 (0.50) | SSTR4HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109233786-B | High-temperature-resistant clean fracturing fluid and preparation method thereof | 河南省科学院高新技术研究中心 | 2021-03-26 | — | — | CN | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-4274862-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-06-23 | — | — | US | claimed |
| JP-57058652-A | — | — | None | — | — | JP | disclosed |
| JP-55104240-A | — | — | None | — | — | JP | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006135627-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-0641781-B1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5478838-A | Treating hypertension, angina pectoris, asthma, improving peripheral circulation | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0641781-A1 | 4-AMINO(ALKYL)CYCLOHEXANE-1-CARBOXAMIDE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| JP-S5758652-A | N-ALPHA,-ALPHA-DIMETHYLBENZYLACETAMIDE DERIVATIVE AND HERBICIDE | SHOWA DENKO KK | 1982-04-08 | — | — | JP | disclosed |
| US-4274862-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-06-23 | — | — | US | disclosed |
| US-4274862-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-06-23 | — | — | US | disclosed |
| JP-S55104240-A | N-(ALPHA,ALPHA-DIMETHYLBENZYL)-ACETAMIDE DERIVATIVE AND HERBICIDE CONTAINING THE SAME | IDEMITSU KOSAN CO LTD | 1980-08-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SSTR4 3594/4885HDAC3 1946/4885HDAC1 1147/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SSTR4 3572/4885HDAC3 2044/4885HDAC1 1233/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SSTR4 3594/4885HDAC3 1946/4885HDAC1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.